Kinetics of Alloantigen-Specific Regulatory CD4 T Cell Development and Tissue Distribution After Donor-Specific Transfusion and Costimulatory Blockade

Yusuke Tomita, MD,1 Miwa Satomi, MD,1 William Bracamonte Baran, MD, PhD,1 Ewa Jankowska Gan, MS,1 Andrea Szymczak Workman, PhD,2 Greg J. Workman, PhD,2 Dario Angelo Alberto Vignali, PhD,2 William J. Burlingham, PhD1

Background. The influence of donor-side regulation toward recipient antigens on graft outcome is poorly understood.

Methods. Because this influence might be due in part to the accumulation of tissue-resident memory T cells in the donor organ, we used a standard murine tolerization model (donor-specific transfusion plus CD40L blockade) to determine the kinetics of development and peripheralization of allo-specific regulatory T cell in lymphoid tissues and liver, a secondary lymphoid organ used in transplantation.

Results. We found that donor-specific transfusion and CD40L blockade leads to a progressive and sustained T regulatory allo-specific response. The cytokines IL10, TGFβ, and IL35 all contributed to the regulatory phenomenon as determined by trans vivo delayed hypersensitivity assay. Unexpectedly, an early and transient self-specific regulatory response was found as well. Using double reporter mice (forkhead box p 3 [Foxp3]-yellow fluorescent protein, Epstein-Barr virus-induced gene 3 [Ebi3]-TdTomRed), we found an increase in Foxp3+CD25+ regulatory T (Treg) cells paralleling the regulatory response. The Ebi3+ CD4 T cells (IL35-producing) were mainly classic Treg cells (Foxp3+CD25+), whereas TGFβ+ CD4 T cells are mostly Foxp3-negative, suggesting 2 different CD4 Treg cell subsets. Liver-resident TGFβ+ CD4 T cells appeared more rapidly than Ebi3-producing T cells, whereas at later timepoints, the Ebi3 response predominated both in lymphoid tissues and liver.

Conclusions. The timing of appearance of donor organ resident Treg cell subsets should be considered in experiments testing the role of bidirectional regulation in transplant tolerance.

(Transplantation Direct 2016;2: e73; doi: 10.1097/TXD.0000000000000580. Published online 21 April 2016.)

The adaptive alloimmune response of the host direct, semidirect, and indirect allore cognition by T cells, and allo-specific B cells is thought to be responsible for rejection of organ transplants.1–3 Several therapeutic treatments are needed to control the immune response and prolong graft survival. Nevertheless, in current clinical practice, most of these treatments generate global immune suppression and as consequence increase the risk of severe and even life-threatening opportunistic infections. Furthermore, most of these drugs have significant side effects affecting the cardiovascular, endocrine, and hematologic systems.4,5

In contrast, the best possible outcome after transplantation would be the development of graft-specific tolerance, in such a way that the immune system becomes unresponsive to graft-derived antigens without the need of immunosuppressive drugs.6 A still suboptimal but desirable condition is the development of donor-specific regulation in the recipient immune system, which is not sufficient to achieve complete tolerance, but is associated with longer graft survival and increased likelihood of successful withdrawal of immunosuppressive drugs.7,8 Notwithstanding, the induction of allo-specific tolerance or regulation is still challenging, partially because some physiologic aspects of regulation development, particularly on the donor side, are still unknown.6

Received 21 December 2015. Revision requested 15 January 2016. Accepted 4 February 2016.

1 Division of Transplantation, Department of Surgery, University of Wisconsin-Madison, WI.
2 Department of Immunology, University of Pittsburgh, Pittsburgh, PA.

This work was supported by the National Institutes of Health (R01 A0066219-08 to W.J.B. and R01 A0091977 to D.A.V.) and Department of Surgery in UW-Madison (to W.J.B.).

The authors declare no conflicts of interest.

Y.T. and M.S. contributed equally to this work.

Y.T., W.B.B., D.A.V., and W.J.B. participated in research design. Y.T., W.B.B., and W.J.B. participated in the writing of the article. Y.T., M.S., W.B.B., E.J.G., A.S.W., and C.J.W. participated in the performance of the research. Y.T., W.B.B., E.J.G., D.A.V., and W.J.B. contributed new reagents or analytic tools. Y.T., W.B.B., and W.J.B. participated in data analysis.

Correspondence: William J Burlingham, Division of Transplantation, Department of Surgery, University of Wisconsin, Madison, WI 53792. (burlingham@surgery.wisc.edu).

Copyright © 2016 The Authors. Transplantation Direct. Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited.

ISSN: 2373-8731
DOI: 10.1097/TXD.0000000000000580
To analyze the role of donor-side regulation toward recipient antigens, we chose to study a mouse model, including lymphoid tissues and a secondary lymphoid organ typically used in vascularized organ transplantation, where donor-specific transfusion (DST) and anti-CD40L monoclonal antibody are a well-known protocol to induce allospecific tolerance. Such treatment, when applied to a future transplant donor, could give us insights as to the type of tissue-resident lymphocytes that give rise to bidirectional regulation in organ transplantation. It is known that DST and anti-CD40L treatment can induce forhead box p3 [Foxp3]+ regulatory T (Treg) cells, and IL10 as well as and TGFβ secretion by allospecific Treg cells. Far less is known about the induction of IL35-secreting T cells. Meanwhile, the alloreactive effector T cell clones are depleted, anergized, or shifted to regulatory functions by the CD40L blockade during the alloresponse induced by DST, whereas other T-cell clones are minimally affected.

One way that host-based regulation approaches may fail to achieve long-term tolerance is the absence of a regulatory response on donor side. For example, the highest level of pretransplant regulation, both in rhesus macaques and in human, was directed to noninherited maternal antigen (NIMA). Yet analysis of more than 10,000 live-related kidney transplants in the United States has shown that transplants from a maternal kidney donor fare worse than any other type of 1 HLA haplotype-mismatched graft within a family. In contrast, grafts from a sibling kidney transplant donor fared much better if the mismatched HLA haplotype was the NIMA, as compared with the noninherited paternal, or noninherited paternal antigen, mismatched siblings. One possible explanation for this, so-called NIMA paradox, is that the sibling donor’s immune response to the host is also a NIMA response, that is, conditioned by microchimerism and development in the same mother as the host. The maternal donor’s response to the offspring as host is a memory response to inherited paternal antigens of her child and thus may be a sensitized response, subverting tolerance induction. Analysis of graft outcomes in a group of 18, 1 HLA haplotype-mismatched donor-recipient pairs enrolled in a depletion protocol showed poor graft survival in cases where the recipient strongly regulated to donor antigens before transplant, whereas the donor did not regulate to the recipient. In contrast, excellent long-term outcome was seen in cases where both donor and recipient regulated to each other’s antigen before transplantation.

IL35, a member of the IL12 family of cytokines, is a heterodimeric cytokine comprising the p35 (α-chain) shared by IL12 and Epstein-Barr virus-induced gene 3 (Ebi3) (β-chain) shared by IL27. The IL35 receptor is composed of gp130, the receptor for IL6 and the IL12 receptor β2. IL35 was first reported by Vignali et al, and subsequently of gp130, the receptor for IL6 and the IL12 receptor was the NIMA, as compared with the noninherited paternal, donor fared much better if the mismatched HLA haplotype

We hypothesized that Treg cells developed in response to DST and MR-1 will exhibit alloantigen specificity, appear to other tissues besides the lymph nodes and spleen, where they produce immunosuppressive cytokines in response to specific tolerogen, and thereby mediate allospecific linked suppression of delayed type hypersensitivity (DTH), a pre-condition for bidirectional regulation after transplant of that organ. In this study, we investigated the characteristics of the peripheral Treg cells induced by DST and anti-CD40L treatment. We were particularly interested in the kinetics of their development, and their migration into secondary lymphoid (transplantable) tissues, where they could potentially serve as facilitators of a robust tolerance via bidirectional regulation.

MATERIALS AND METHODS

Mice

Mice were bred and maintained at the University of Wisconsin-Madison Hospital animal facilities according to specific pathogen-free conditions. All animal care and handling were performed under institutional guidelines. C57 BL/6 (B6) [H2b], CBA/J (CBA) [H2k], and DBA/2 [H2d] were purchased from Harlan Sprague Dawley (Indianapolis, IN). In addition, it was used a specific strain of double reporter transgenic mice expressed YFP under the Foxp3 promoter and Td-Tomato-Red (TdTomRed) under the Ebi3 promoter (C57BL/6 background). In addition, we used a specific strain of double reporter transgenic mice expressed YFP under the Foxp3 promoter and Td-Tomato-Red (TdTomRed) under the Ebi3 promoter (C57BL/6 background). Homozygous males and females were used to establish breeding pairs and maintain the colony in a BSL-2 facility (Medical Science Center, University of Wisconsin-Madison). Reporter expression was confirmed by flow cytometry. We chose to use tolerance induction by DST and anti-CD40L monoclonal antibody (MR-1), as a means to analyze our hypothesis.

Study Design

Figure 1 shows the experimental timeline, including the time points when tetanus toxoid (TT)/diphtheria toxoid (DT) immunization, DST and MR-1 treatment, euthanized for trans vivo DTH (tv-DTH) and flow cytometry assays were performed. We immunized wild-type and double reporter B6 mice with 70 μg TT/DT pediatric vaccine by subcutaneous injection in their inguinal pouch 2 weeks before initiation of the tolerance protocol. We tolerated those mice with 1.0 x 107 CBA spleen cells (200 μL) by retro orbital intravenous injection (DST) on day 0 and MR-1 (Bio X Cell) by intraperitoneal injection of 125 μg/dose on days 0, 2, and 4. In this model the CBA haplotype [H2k] is considered the “donor.” Mice were euthanized on days 14, 35, and 70, spleen and lymph nodes (inguinal, axially, and surgical cervical) were harvested. Trans vivo DTH was performed using splenocytes, whereas flow cytometry was performed with lymph nodes, splenocytes, and liver cells.

Tissues Processing

Spleen tissue was mechanically separated with microforceps and 100-μm nylon strainer. After washing on
phosphate-buffered saline, red blood cells and platelets were lysed with ammonium-chloride-potassium lysing buffer and then washed. After cell counting, splenocytes were resuspended in desired volume. Lymph nodes were just mechanically separated with microforceps and 100-μm cell strainer, and then washed in PBS. To generate single-cell suspensions from liver tissues, it was mechanically separated with microforceps and a 100-μm cell strainer. Then, suspension was incubated with collagenase IV (2 mg/mL) and DNAse I (0.2 mg/mL) at 37°C for 60 minutes. After washing with PBS, cells were mononuclear cells enriched using Percoll buffer (35%). Red blood cells were lysated with ammonium-chloride-potassium lysing buffer, and finally the cell suspension washed with PBS.

Tv-DTH Assay

We used the mouse-to-mouse DTH transfer assay protocol described previously.17,20,21 Briefly, 1.0 × 10^7 splenocytes of B6, CBA, or DBA/2 were washed twice in sterile PBS, and resuspended in 0.1 mL PBS containing 10 μg/mL phenylmethylsulfonyl fluoride (Sigma-Aldrich). The cells were then sonicated using a VR50 sonicator fitted with a 2-mm probe (Sonics). The disrupted cells were centrifuged for 30 min at 14 000g at 4°C to remove debris. The protein content of the supernatant was determined using a micro BCA Protein Assay kit (Pierce). A total of 20 μg of protein was used for each injection in the DTH assays and referred to as either B6 [syngeneic/self], CBA [allogeneic/donor], or DBA/2 [3rd party] Ag. At the time points indicated in Figure 1, we euthanized and recovered a spleen, then washed. After cell counting, splenocytes were resuspended in 0.1 mL PBS containing 10 μg/mL phenylmethylsulfonyl fluoride (Sigma-Aldrich). The cells were then sonicated using a VR50 sonicator fitted with a 2-mm probe (Sonics). The disrupted cells were centrifuged for 30 min at 14 000g at 4°C to remove debris. The protein content of the supernatant was determined using a micro BCA Protein Assay kit (Pierce). A total of 20 μg of protein was used for each injection in the DTH assays and referred to as either B6 [syngeneic/self], CBA [allogeneic/donor], or DBA/2 [3rd party] Ag. At the time points indicated in Figure 1, we euthanized and harvested a spleen, recovered splenocytes, and performed a tv-DTH assay. Specifically, we injected 1.0 × 10^6 splenocytes from treated mice into syngeneic naïve mice footpads plus either: PBS [negative control], TT/DTD recall antigen (25 μg) [positive control], test antigen (20 μg) [B6, CBA, or DBA/2 cell lysate], or a combination of TT/DTD and test Ag [for linked suppression determination]. It is essential to notice that spleen cells DST is more efficient than bone marrow cells DST in regulation induction. Before injection and after 24 hours, we used a dial-thickness gauge to measure footpad thickness; change in thickness, after subtraction of PBS value [net swelling] was expressed in units of 1.0 × 10^-4 inches. To determine the extent of “linked suppression” we used the following formula:

\[
\% \text{Inhibition} = \left(1 - \frac{(TT \text{ plus antigen})\text{response}}{TT\text{response}}\right) \times 100
\]

The linked suppression was determined by comparing the footpad swelling response to TT/DTD recall antigen alone, with the response to the combination of TT/DTD and test antigen. The results were expressed as % inhibition of the recall response. When the % inhibition value with syngeneic Ag was equal or greater than the % inhibition value with allogeneic-Ag, we considered the regulation in the mouse to be entirely nonspecific. When the % inhibition value with syngeneic Ag was less than the % inhibition value with allogeneic-Ag, we considered this to be evidence of allospecific regulation. All values represent the observed tv-DTH response for the respective group minus the PBS control. Coinjected blocking antibodies were: αTGFβ (BD Pharmigen) (10 μg), αIL10 (R&D Systems) (10 μg), a combination of αp35 (R&D Systems) + αEbi3 (provided by Dr. Vignali, University of Pittsburgh) (1 μg of each), and αIL4 (BD Bioscience) (10 μg).

A scheme of how this assay might detect linked suppression caused by self- or allogeneic-Ag, is shown in Figure 2. The functionality of memory allo-specific Treg cells was analyzed using tv-DTH assay. In this “single APC” model, suppression of the footpad swelling to TT/DTD is “linked” when antigen sonicate is coinjected, because both the effector T-cell recognizing TT/DTD peptide, and Treg cells recognizing either self-peptide or allopeptides are seeing their p/MHC ligand on the same APC. If the APC is a dendritic cell, there is the possibility of thrombospondin- and indoleamine 2, 3-dioxygenase-mediated “trans” suppression effects.11 The APC-Treg cell interactions also result in production of regulatory cytokines IL10, TGFβ, or IL35.

Flow Cytometry Assay

Fluorochrome-labeled monoclonal antimouse antibodies were used at proper concentrations according to vendor technical sheets and/or titration experiments in our laboratory.
Cells from spleen and lymph nodes were harvested and stained with CD3 (145-2C11), CD4 (RM4-5), CD25 (PC61), TGFβ/LAP (TW7-16B4) for 30 minutes at 4°C in FACS buffer. Depending on the panel, the following fluorochromes were used: eFlour450, BV421, APC, Alexa700, APC-eFlour780. Antibodies were purchased either from eBioscience, BD Bioscience, or Biolegend. Fc blocking was made with anti-CD16/32 Ab. Fluorescein isothiocyanate (or equivalents) and PE (or equivalents) were avoided because they overlap the emission range of YFP and TdTomRed, respectively. YFP has an excitation peak at 514 nm and the emission peak is 527 nm (capture by 488B standard channel in flow cytometry). TdTomRed has an excitation peak of 557 nm and emission peak of 592 nm (captured by 561E standard channel). Flow cytometric analysis was performed on a BD FACS LSRII bench-top analyzer (BD Bioscience, San Jose, CA) and analyzed using FlowJo version 10 (Tree Star, Ashland, OR).

**FIGURE 2.** Trans vivo DTH bioassay. When naive B6 mice are used as recipients of footpad injection for the adoptive transfer of cells from TT-immunized, CBA-tolerized B6 hosts, cotransfer of spleen cells plus TT/DT results in activation of specific effector T cells, and a footpad swelling response relative to PBS control challenge is measured at 24 hrs (red bars in graph below diagram). When the splenocytes are cocojected with alloantigen (crude CBA spleen cell lysate, 14 000g supernatant) as well as TT, indirect allopresentation will activate the allopeptide-specific memory regulatory T cells developed during DST and MR-1 treatment. Those cells will then release anti-inflammatory cytokines that can counterbalance the TT-induced response (linked suppression). The lower left depicts the results of an assay in which only donor-specific Treg cells are present in the transferred responder cells. The lower right depicts the results of an assay in which both self-antigen specific (white bars) and donor-specific (blue bars) Treg cells are present. In either case, the regulatory phenomenon may be probed to see if coinjected blocking antibodies neutralize any cytokines produced by the regulatory T cells and restore the TT/DT response.

**RESULTS**

**DST + CD40L Blockade Induced a Transient Regulatory Response to Self-Antigens But Persistent Allospecific Immunoregulation**

First, we determined the time course of allospecific regulation as a measure of the immune regulatory response. The timeline of treatment of the mice and harvest of spleen, lymph nodes, and liver is shown in Figure 1. The functionality of memory allospecific Treg cells was analyzed at various times after the DST and anti-CD40L blockade treatment using

**Statistical Analysis**

Statistical analyses were performed by Graphpad Prism (GraphPad Software v5.01, San Diego, CA). The P values were calculated using Student t tests and with 95% confidence interval set as the measure of statistical significance (*P ≤ 0.05, **P < 0.01, ***P < 0.001).
the tv-DTH–linked suppression assay. Figure 2 shows 1 view of how linked suppression of tv-DTH may occur in this assay. Regulatory T cells recognizing an allopeptide or a self-peptide may be activated to release IL10, TGFβ, or IL35, suppressing the TT/DT-specific recall response.

We found that DST and anti-CD40L blockade induced a sustained allospecific regulation toward CBA antigen (H2k). This regulatory effect was already evident on day 14 after treatment and persisted for up to 70 days after treatment ($P < 0.001$ on day 35 and $P < 0.001$ on day 70, respectively) (Figure 3A). Also, the magnitude of the allospecific regulation increased between days 14 and 35 (Figures 3A, B). As expected, we found no regulation toward third-party antigens (DBA/2; H2d). Unexpectedly, we observed linked suppression induced by self-antigens (B6; H2b) on day 14 ($P \leq 0.05$). This regulation occurred only at this early time point and disappeared by day 35 ($P = \text{N.S.}$, % linked suppression with B6 antigen vs TT alone). On days 35 and 70 neither self H2b nor third-party H2d antigens elicited linked suppression of tv-DTH, suggesting that self-reactive Treg cells developed quickly, but subsided quickly in response to tolerization treatment (Figure 3B).

To determine if the DST was required or if MR-1 alone was sufficient to cause linked suppression, similar experiments were performed on mice that received just MR-1 injections (Figure 3C). In this case, no linked suppression was seen, either on day 14 or day 35, consistent with the known mechanism of action for costimulatory blockade treatments, in which specific antigen challenge, and subsequent T cell-APC engagement are required to achieve the tolerogenic effect.

**Immune-Suppressive Cytokines Are Required for DST + CD40L Blockade-Induced Regulation**

Following the same experimental protocol, the tv-DTH assay was used to determine the regulatory cytokines that mediate linked suppression. In this case, splenocytes from mice treated with DST and MR-1 were transferred into footpads of naive syngeneic B6 mice and coinjected with TT/DT recall antigens, alloantigens, and blocking antibodies: (a) αIL10, (b) αTGFβ, or (c) αEbi3+αIL12p35 (αIL35). On day 35, all 3 blocking antibodies uncovered the allosresponse, abrogating the regulatory phenomenon, suggesting that all 3 cytokines are involved in the allospecific regulation developed after DST and MR-1 treatment (Figure 4). The coinjection of IgG isotype control did not elicit a significant effect, whereas αIL4 had only a marginal impact in linked-suppression. This profile was similar on days 35 and 70 after DST and

![Figure 3](image_url)

**FIGURE 3.** Time course of regulation response after DST and MR-1 tolerization. A, The tv-DTH linked suppression response to syngeneic (B6), allogeneic (CBA), and third-party (DBA/2) antigen prep on days 14, 35, and 70 after the DST and MR-1 treatment. Splenocytes from tolerized B6 mice at each time-point were tested in tv-DTH assay. The TT/DT response represents the positive control. Responses to TT/DT recall antigen (25 μg) were shown with each test antigen (20 μg) and analyzed by Student t-est ($* P \leq 0.05$; *** $P < 0.001$). Data were presented as mean with SEM from 6 to 9 mice in each group (open symbols; wild type B6 mice, close symbols; Foxp3/YFP, TdTomRed/Ebi3 reporter B6 mice). B, Timeline of the linked suppression. Here is plotted in the Yaxis the “% inhibition,” that is, percentage of decrease in the TTresponse in response to the coinjection of each antigen [self B6, donor CBA, and third-party DBA/2]. Although self plus allospecific regulation was observed on day 14 after DST and MR-1 treatment, allospecific regulation had developed in the central lymphoid tissue by day 35. There was no regulation at any time toward third-party Ag. Self-regulation was transient at early time-points, whereas allospecific regulation increased over-time, reaching a plateau on day 70. C, Isolated impact of CD40L blockade. The footpad swellings to TT/DT challenge were not inhibited by any of the 3 antigens on days 14 and 35. Data were presented as mean with SEM from 3 mice in each group and analyzed by Student t test.
MR-1 treatment ($P < 0.001$ for all 3, IL10, TGFβ, and IL35 anticytokines versus IgG control on day 35 and on day 70) (day 70 data not shown). These results indicate that the allospecific regulatory phenomenon in the spleen is mediated by IL10, TGFβ, and IL35.

In contrast, self-specific responses were uncovered only in half of the mice by IL10, TGFβ, and IL35 neutralization on day 14. There was no statistically significant abrogation of self-induced linked suppression, although a trend was observed ($P = 0.06$, $P = 0.09$, and $P = 0.06$, respectively).

**Ebi3 Producer and TGFβ Producer Treg Cells Belong to Different Subsets**

The mice used in the first set of experiments were double reporters (Foxp3/YFP and Ebi3/TdTomRed). The expression of the TdTomRed reporter indicates an active transcription of the Ebi3 gene. Epstein-Barr virus-induced gene 3 transcription and surface TGFβ/LAP expression in CD4 T cells of tolerized mice were analyzed with flow cytometry to determine the phenotype of the CD4 T cells producing 2 of the cytokines involved in the allorejection (Figures 5A, B).

Analyzing lymph nodes harvested on day 35 after treatment, we confirmed that approximately 50% of T cells actively transcribing Ebi3 (TdTomRed) were Foxp3+CD25+ Treg cells. We also found that CD4 T cells which actively transcribed Ebi3 and the ones expressing surface TGFβ/LAP were different cells (Figures 5B, C). One third of TGFβ+CD4 T cells showed the typical phenotype of Treg cells (Foxp3+CD25+), but the majority were Foxp3neg, and within those TGFβ+Foxp3neg cells, only half were CD25+. No significant double positive Ebi3/TGFβ proportion was found either in lymph nodes or spleen on day 14; on day 35, this proportion was only slightly increased. Therefore, we conclude that the induced IL35-producing and TGFβ-producing CD4 T cells belong to mostly nonoverlapping subsets.

**Peripheralization of Treg Cells**

To determine the dynamics of regulatory cells development and homing in peripheral tissues, lymph nodes, spleen, and liver were harvested from naive animals, and from mice treated with DST and MR-1, at days 14 and 35.

The Foxp3+CD25+ cells showed an increase over time in primary lymphoid tissues (spleen and lymph nodes) and liver ($P < 0.01$ in lymphoid tissue and $P < 0.001$ in liver on day 35, respectively) (Figures 6B, 7B). However, in liver, the proportion and the absolute number of Foxp3+CD25+ CD4 T cells were lower than that of lymphoid tissues (compare Figure 7B with Figure 6B). The IL35-producing cells (Ebi3/TdTomRed+) had a frequency and an absolute number that significantly increased over time after tolerization treatment in lymphoid tissues and liver, with a similar pattern ($P < 0.001$) in lymphoid tissue and in liver on day 35, respectively (Figures 6D, 7D). The trend of these IL-35+ cells was consistent with that of the Foxp3+CD25+ conventional Treg cells. Interestingly, the kinetics of these cells was different from the TGFβ+ producer CD4 T cells. TGFβ+ CD4 T cells had a similar baseline in spleen and lymph nodes. The proportion and the absolute number of those cells increased at day 35 after DST and MR-1 treatment in a similar magnitude in both lymphoid tissues (Figure 6E). Remarkably, TGFβ-producer cells were nearly absent in the liver at day 0, but its proportion and the absolute number increased significantly on day 14 after treatment ($P < 0.01$ and $P = 0.05$, respectively), with further increase at day 35 ($P < 0.001$ and $P < 0.01$, respectively) (Figure 7E). This suggests a migratory process of the Treg cells into specific peripheral niches. It is interesting that after tolerization treatment, the proportion of TGFβ+ cells among CD4 lymphocytes was significantly higher in the liver as compared with lymphoid tissues. These results indicate that IL35-producing and TGFβ-producing cells may have different migratory kinetics in lymphoid tissues and liver.

**Treg Cells in Tolerized Wild-Type B6 Mice**

To rule out the possibility that the dual-marker B6 mice had unusual Treg cell response kinetics, similar experiments were performed to assess the kinetics of the regulatory CD4
T-cell development in wild-type B6 mice. The spleen, lymph nodes, and liver were harvested from wild-type B6 mice treated with DST and MR-1 at days 14, 35, and 70, and immunostained for CD3, CD4, CD25, and TGFβ/LAP.

As with the double reporter mice, DST and MR-1 treatment induced an increased frequency of CD4+CD25+ cells in lymphoid tissues (Figure 8A). Trends, but no significant differences between nontreated mice and tolerized mice were seen in spleen (P = 0.2 on day 14, P = 0.07 on day 35, and P = 0.06 on day 70, respectively). However, there were significant differences in lymph nodes (P ≤ 0.05 on day 14, P < 0.001 on day 35, and P < 0.001 on day 70, respectively). In liver, CD25+ cells had a very low baseline frequency on day 14 (1.0% of CD4 T cells). These cells increased until day 35 after tolerization, but the proportion was lower than that of lymphoid tissues (P ≤ 0.05 on day 35, and P ≤ 0.05 on day 70, respectively). This trend was consistent with that of the YFP-labeled Foxp3+ subpopulation in double reporter mice (Figures 6B, 7B). Interestingly, the proportion of TGFβ+ cells in CD4 T cells of wild-type B6 mice was lower than that in the double reporter mice (compare Figure 6E and 7E); however, the kinetics of appearance of these cells was similar.

**DISCUSSION**

Pretransplant regulation on the donor side (toward the recipient), as well as the recipient side (toward the donor), led to long-term graft survival of a kidney allograft in a depletional protocol. Donor-derived hematopoietic cells are transferred to the host in organ transplantation, creating a risk of graft versus host disease, whereas stable microchimerism in the recipient was associated with improved long-term graft outcome. Conlon et al showed that host CD4 T cells trafficking into germinal centers provided help for activated B cells to produce IgG alloantibody via the indirect allorecognition pathway, whereas donor-derived hematopoietic cells were able to activate host B cells to get them into germinal centers, but were unable to induce class-switched alloantibody. In rat heart transplantation, Ko et al reported that selective depletion of donor leukocytes...
by antibody 2 weeks after engraftment had no effect upon long-term allograft function. However, passenger leukocyte depletion at the time of transplant was associated with development of severe chronic allograft vasculopathy. Josien et al.\(^{29}\) have also shown that the presence of interstitial allospecific dendritic cells in heart graft can elicit tolerance in CD4 T cells from rats after DST treatment. These results suggested that donor-derived leukocytes in graft might play a role in either undermining, or facilitating successful engraftment both within the local environment of the transplant, and by their impact on distal immune sites.

Our study showed data about the progression of tolerance after DST and anti-CD40L monoclonal antibody treatment. Importantly, while self-specific and allospecific regulation was observed 2 weeks after tolerization, allospecific regulation took approximately 5 weeks to develop in the lymphoid tissue (Figure 3B). In regards to this point, concerning the timing of graft placement in relation to the development of tolerance, we found that 5 weeks after the tolerization treatment was sufficient for allospecific regulation to manifest itself in both the lymphoid tissue and liver. Rosenblum et al.\(^{30}\) reported that there were many tissue resident T cells in transplanted organs, including inflammatory memory T cells and Treg cells. On days 30 to 40 after resolution of an inflammatory response, activated T cells which had appeared from central lymphoid tissue were maintained in the target organ, thus developing “Treg memory” to that organ. This time frame corresponds to the kinetics of development of allospecific-linked suppression responses. Several studies have demonstrated that DST and anti-CD40L monoclonal antibody treatment induced tolerance, as evidenced by long-term tissue or solid organ allograft survival in mice.\(^{31-34}\) In these studies, the transplantation was performed early after treatment (usually <7 days). In fact, in some cases, DST was not performed, but anti-CD40L monoclonal antibody was injected the same day of transplantation, in such a way that the graft itself provided the allogepic challenge needed for the costimulatory blockade to work.\(^{11,35,36}\) Honey et al.\(^{36}\) reported that anti-CD40L monoclonal antibody induced Ag-specific tolerance and linked suppression in CD4 T cells, but not CD8 T cells, suggesting that additional therapies to control aggressive CD8+ T cells may augment the tolerance state. Primarily vascularized skin allografts behaved similarly to heart allografts, whereas conventional skin grafts were not prolonged by anti-CD40L, suggesting that rapid escape of “passenger leukocytes” provides the DST-like stimulus for tolerance induction.\(^{37}\)

Regulatory T cell development in response to alloantigen stimulation by DST appears to rely on host antigen-presenting cells, or the indirect pathway of allrecognition,

FIGURE 6. Time course of increase in CD4 regulatory T cells in tolerized double reporter B6 mice—lymph nodes. A. Gated CD4 T cells in lymph nodes, which were harvested on days 0 (untreated), 14, and 35 after DST and MR-1 treatment, were analyzed for Foxp3+ (reporter) and CD25+ by flow cytometry. B. Comparison of the frequency and the total number of Foxp3+CD25+ cells in spleen and lymph nodes cells on day 0, 14, and 35 after the tolerized treatment. Total cell number means the absolute Foxp3+CD25+ CD4 T cells recovered from the same spleen and lymph nodes. C. Gated CD4 T cells in lymph nodes over time after DST and MR-1 treatment were analyzed for Ebi3+ (reporter) and TGFβ/LAP+ by flow cytometry. D, E. Comparison of the frequency and the total number of Ebi3+ (D) and TGFβ/LAP+ (E) cells in lymphoid tissues on day 0, 14, and 35 after the tolerized treatment. Data were presented as mean from 4–7 mice in each group and analyzed by Student t test (*P ≤ 0.05; **P < 0.01; ***P < 0.001; Close symbols; spleen, Open symbols; lymph nodes).
as early studies showed a requirement for MHC antigen sharing between host and donor in order for graft prolongation by F1 DST alone.\(^3\) Fully allogeneic DST did not prolong heart allograft survival. Costimulation blockade with anti-CD40L monoclonal antibody permits tolerization with a fully allogeneic DST. However, few studies have addressed the kinetics of allospecific Treg cell induction on the key indirect allorecognition pathway. Burrell and Bromberg\(^1\) showed an early phase burst of proliferation and Foxp3 conversion of transferred allospecific “indirect pathway” T cells in the first 72 hours after transfusion of BALB/c cells into B6 mice treated with anti-CD40L monoclonal antibody. This induced Treg (iTreg) induction occurred mainly in the lymph nodes. Follow-up studies by the same group found that rapid matrix remodeling of the lymphoid vessels occurring within hours after DST and anti-CD40L monoclonal antibody treatment was essential for the early burst of T-cell proliferation resulting in allospecific iTreg,

FIGURE 7. Time course of increase in CD4 regulatory T cells in tolerized double reporter B6 mice—liver. A, Gated CD4 T cells in liver, which were harvested on day 0 (untreated), 14, and 35 after DST and MR-1 treatment, were analyzed for Foxp3+ (reporter) and CD25+ by flow cytometry. B, Comparison of the frequency and the total number of Foxp3+/CD25+ cells in liver on day 0, 14, and 35 after the tolerized treatment. C, Gated CD4 T cells in liver over time after DST and MR-1 treatment were analyzed for Ebi3+ (reporter) and TGFβ+LAP+ by flow cytometry. D, Comparison of the frequency and the total number of Ebi3+ (D) and TGFβ+LAP+ (E) cells in liver on days 0, 14, and 35 after the tolerized treatment. Data were presented as mean from 4 to 6 mice in each group and analyzed by Student t test (*P < 0.05; **P < 0.01).

FIGURE 8. Organ distribution patterns in spleen, lymph nodes, and liver of freshly harvested regulatory CD4 T lymphocytes of tolerized wild-type B6 mice. A, Gated CD4 T cells in lymph nodes, which were harvested on day 0 (untreated), 14, 35, and 70 after DST and MR-1 treatment, were analyzed for CD25+ and TGFβ+LAP+ by flow cytometry. B, Comparison of the frequency and the total number of CD4+CD25+ cells in spleen, lymph nodes, and liver over time after the treatment. B, Comparison of the frequency and the total number of Ebi3+ (D) and TGFβ+LAP+ (E) cells in liver on days 0, 14, and 35 after the tolerized treatment. Data were presented as mean from 2 to 3 mice in each group and analyzed by Student t test (*P < 0.05; **P < 0.01, close symbols; spleen, open symbols; lymph nodes, and triangle symbols; liver).
whereas by day 7 transfer of the same TcR transgenic T cell resulted in anergy and apoptosis. This suggests a 2-phase model of naive conventional T to Foxp3+ Treg cell conversion, followed by a phase in which tolerance may be based on allospecific T-cell anergy. Our studies have identified yet a third phase: the evolution of a robust, donor-specific immunoregulatory response, involving both Foxp3+ and Foxp3neg CD4 T cells.

The proportion of regulatory Foxp3+, TGFβ+, and Ebi3-producing CD4 T cells increased in lymphoid and peripheral tissues over time. The flow cytometry results corroborated the functional analysis of the regulatory function, that is, the increase in regulatory CD4 T cells paralleled the increase of allospecific-linked suppression in tv-DTH assay. We found that the allospecific regulatory phenomenon in the spleen on day 35 was mediated by IL10, TGFβ, and IL35. It is important to note that, in previous studies of mouse and human, the regulation detected in the linked suppression tv-DTH assay was reversed by anti-Ebi3 and by anti-p35 tested separately, whereas anti-p28, the subunit of IL27 associated with Ebi3, had no effect. This suggests that the effects we are seeing are indeed due to the action of IL35. In a previous study by Maynard et al., it was found using a IL10 and Foxp3 dual reporter mouse that leukocytes distributed to lung and liver were enriched in Foxp3+IL10neg Treg cells, whereas the gut-homing Treg cells included both Foxp3+IL10+ and Foxp3neg IL10+ subsets. Thus, the tissue specificity of different types of Treg cells makes it important to consider the organ that is being transplanted, as far as bidirectional regulation is concerned. Interestingly, the TGFβ-producing and IL35-producing cells were different in Foxp3 phenotype (Figures 5B, C). This was compatible with previous studies showing that, within the CD4 T cells, IL35 was secreted by classic Foxp3+ Treg cells but not by Th0 or activated T effector cells. Induction of allospecific IL35-producing Treg cells is implied by the abolition of tv-DTH-linked suppression. Because this induction occurs after allogeneic challenge, the Ag-specific Treg cells were most likely a peripheral (or inducible) type. Nevertheless, the possibility that DST-derived migratory dendritic cells can influence thymic Treg cell development cannot be entirely ruled out. In contrast to the Ebi3-producing Treg cells, the majority of cells producing TGFβ were Foxp3neg (Figure 5C), as previously reported. The precise identity of the TGFβ+ CD4 T cells has yet to be determined—they might be either Th1 cells or, alternatively, “Th3” CD4 T effector cells that synthesize the cytokine as part of their effector program.

We also found that TGFβ-producing and IL35-producing cells both appeared in the liver, but with different kinetics. Remarkably, TGFβ-producing cells appeared into peripheral tissues (liver) significantly faster than did IL35-producing cells. TGFβ-producing cells appeared in liver at day 14 after treatment, whereas IL35-producing CD4 T cells reached a maximum at day 35 (Figure 7D vs Figure 7E). Also, the fold-increase compared with baseline status was higher for TGFβ-producing CD4 T cells.

Bidirectional regulation implies a pretransplant induced unresponsiveness of the recipient immune system to donor antigens, and vice versa. The beneficial effects of this condition have been described in leukodepleted posttransplant kidney patients. Regarding the application of our data to the study of bidirectional regulation in primarily vascularized transplant models, the results suggest that mice to be used as transplant donors should receive tolerization treatment at least 35 days before transplantation to allow regulatory cells to home to the organ.

**ACKNOWLEDGMENTS**

The authors would like to thank Kazuhiko Yamada for his helpful advice and Kate Vignali for assistance with assay development.

**REFERENCES**

1. Monguíó-Tortajada M, Lauzarria-Valdemoros R, Borràs FE. Tolerance in organ transplantation: from conventional immunosuppression to extracelluar vesicles. Front Immunol. 2014;5:416.
2. Horvitz P, Lechner R. Direct and indirect pathways of allostentigen recognition: relevance to acute and chronic allograft rejection. Nephrol Dial Transplant. 1997;12:1806–1810.
3. Benichou G. Direct and indirect antigen recognition: the pathways to allograft immune rejection. Front Biosci. 1999;4:D476–D480.
4. Adams DH, Sanchez-Fueyo A, Samuel D. From immunosuppression to tolerance. J Hepatol. 2015;62:S170–S185.
5. Sircar A, Koegel A, Morelon E, et al. Cell therapy to induce allograft tolerance: time to switch to plan B?Front Immunol. 2015;6:149.
6. Kawa T, Leventhal J, Madsen JC, et al. Tolerance: one transplant for life. Transplantation. 2014;98:117–121.
7. Scandling JD, Busque S, Dejbaksh-Jones S, et al. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant. 2012;12:1133–1145.
8. Kawa T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008;359:353–361.
9. Hará M, Kingsley CI, Nimni M, et al. IL-10 is required for regulatory Tcells to mediate tolerance to allostentigen in vivo. J Immunol. 2001;168:3789–3796.
10. Bickerstaff AA, VanBuskirk AM, Wakely E, et al. Transforming growth factor-beta and interleukin-10 subvert alloreactive delayed type hypersensitivity in cardiac allograft acceptor mice. Transplantation. 2000;69:1517–1520.
11. Conde P, Rodríguez M, van der Touw W, et al. DC-SIGN(+) macrophages control the induction of transplantation tolerance. Immunity. 2015;42:1143–1158.
12. Burrell BE, Bromberg JS. Fates of CD4+ T cells in a tolerant environment on timing and place of antigen exposure. Am J Transplant. 2012;12:576–589.
13. Büringh WJ, Jankowska-Gan E, Kempston S, et al. Patterns of immune regulation in rhesus macaque and human families. Transplantation Direct. 2015;1:1–10.
14. Miles CD, Schaubel DE, Liu D, et al. The role of donor-recipient relationship in long-term outcomes of living donor renal transplantation. Transplantation. 2008;85:1483–1488.
15. Büringh WJ, Graier AP, Heisey DM, et al. The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors. N Engl J Med. 1998;339:1657–1664.
16. Büringh WJ, Benichou G. Bidirectional alloreactivity: a proposed microchimerism-based solution to the NIMA paradox. Chimerism. 2012;3:29–36.
17. Jankowska-Gan E, Sheka A, Sollinger HW, et al. Pretransplant immune regulation predicts allograft outcome: bidirectional regulation correlates with excellent renal transplant function in living-related donor-recipient pairs. Transplantation. 2012;93:283–290.
18. Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450:566–569.
19. Turris ME, Savant DV, Szymczak-Workman A, et al. Interleukin-35 limits anti-tumor immunity. Immunity. 2016;44:316–329 in press.
20. Molitor-Dart ML, Andrassey J, Haynes LD, et al. Tolerance induction or sensitization in mice exposed to noninherited maternal antigens (NIMA). Am J Transplant. 2008;8:2307–2315.
21. Duttia P, Dart M, Roenningen DA, et al. Pretransplant immune-regulation predicts allograft tolerance. Am J Transplant. 2011;11:1296–1301.
22. Matzman JS, Turka LA. T-cell costimulatory blockade in organ transplantation. Cold Spring Harb Perspect Med. 2013;3:a015337.
23. Murase N, Starzl TE, Tanabe M, et al. Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. *Transplantation*. 1995;60:158–171.

24. Starzl TE, Demetris AJ, Murase N, et al. Cell migration, chimerism, and graft acceptance. *Lancet*. 1992;339:1579–1582.

25. Starzl TE, Zinkernagel RM. Antigen localization and migration in immunity and tolerance. *N Engl J Med*. 1998;339:1905–1913.

26. Starzl TE, Demetris AJ. Transplantation tolerance, microchimerism, and the two-way paradigm. *Theor Med Bioeth*. 1998;19:441–455.

27. Conlon TM, Saeb-Parsy K, Cole JL, et al. Germinal center alloantibody responses are mediated exclusively by indirect-pathway CD4 T follicular helper cells. *J Immunol*. 2012;188:2643–2652.

28. Ko S, Deiwick A, Jäger MD, et al. The functional relevance of passenger leukocytes and microchimerism for heart allograft acceptance in the rat. *Nat Med*. 1999;5:1292–1297.

29. Josien R, Heslan M, Brouard S, et al. Critical requirement for graft passenger leukocytes in allograft tolerance induced by donor blood transfusion. *Blood*. 1998;92:4539–4544.

30. Rosenblum MD, Gratz IK, Paw JS, et al. Response to self antigen imprints regulatory memory in tissues. *Nature*. 2011;480:538–542.

31. Zheng XX, Markees TG, Hancock WW, et al. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. *J Immunol*. 1999;162:4983–4990.

32. Markees TG, Phillips NE, Gordon EJ, et al. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+)+ T cells, interferon-gamma, and CTLA4. *J Clin Invest*. 1998;101:2446–2455.

33. Chai JG, Ratnasothy K, Bucy RP, et al. Allospecific CD4+ T cells retain effector function and are actively regulated by Treg cells in the context of transplantation tolerance. *Eur J Immunol*. 2015;45:2017–2027.

34. Kalache S, Lakhani P, Heeger PS. Effects of preexisting autointimunity on heart graft prolongation after donor-specific transfusion and anti-CD154. *Transplantation*. 2014;97:12–19.

35. Kant CD, Akiyama Y, Tanaka K, et al. Both rejection and tolerance of allografts can occur in the absence of secondary lymphoid tissues. *J Immunol*. 2015;194:1364–1371.

36. Honey K, Cobbold SP, Waldmann H. CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression. *J Immunol*. 1999;163:4805–4810.

37. Ochando JC, Homma C, Yang Y, et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. *Nat Immunol*. 2006;7:652–662.

38. Niimi M, Witzke O, Bushell A, et al. Nondepleting anti-CD4 monoclonal antibody enhances the ability of oral alloantigen delivery to induce indefinite survival of cardiac allografts: oral tolerance to alloantigen. *Transplantation*. 2000;70:1524–1528.

39. Warren KJ, Ivami D, Harris DG, et al. Laminins affect T cell trafficking and allograft fate. *J Clin Invest*. 2014;124:2204–2218.

40. Park AC, Huang G, Jankowska-Gan E, et al. Mucosal administration of collagen V ameliorates atherosclerotic plaque burden by inducing IL-35-dependent tolerance. *J Biol Chem*. 2016;291:3359–3370.

41. Olson BM, Jankowska-Gan E, Becker JT, et al. Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. *J Immunol*. 2012;189:5690–5691.

42. Maynard CL, Harrington LE, Janowski KM, et al. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3– precursor cells in the absence of interleukin 10. *Nat Immunol*. 2007;8:931–941.

43. Torrealba JR, Katayama M, Fehcher JH, et al. Metastable tolerance to rhesus monkey renal transplants is correlated with allograft. TGF-beta 1+CD4+ Tregulatory cell infiltrates. *J Immunol*. 2004;172:5753–5764.

44. Xu Q, Lee J, Jankowska-Gan E, et al. Human CD4+CD25low adaptive T regulatory cells suppress delayed-type hypersensitivity during transplant tolerance. *J Immunol*. 2007;178:3983–3995.

45. Carrier Y, Yuan J, Kuchroo VK, et al. Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice. *J Immunol*. 2007;178:179–185.

46. Carrier Y, Yuan J, Kuchroo VK, et al. Th3 cells in peripheral tolerance. II. TGF-beta-transgenic Th3 cells rescue IL-2-deficient mice from autoimmunity. *J Immunol*. 2007;178:172–178.